Qure.ai
FDA-cleared AI radiology platform detecting TB, stroke, lung cancer and fractures across 105+ countries
Overview
Qure.ai is a Mumbai-based medical AI company building FDA-cleared deep-learning tools for chest X-rays, head CTs, and fractures, deployed across 4,800+ sites in 105+ countries and cited twice in WHO TB guidelines. It holds 26 FDA clearances across 9 products, impacting an estimated 45 million lives.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 31 Aug 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Per-scan or annual subscription models
- Single product / department rollout
- Demo via sales
- Multiple AI products across departments
- PACS/RIS integration and support
- Volume-based contract pricing
Use cases
What you can produce with Qure.ai
- Automated chest X-ray report flagging up to 30 abnormalities with bounding-box overlays, ready for radiologist review within seconds
- Prioritised worklist for head CT scans with suspected intracranial bleeds, mass effect, or cranial fractures, enabling faster treatment decisions
- Lung nodule volumetric measurements and risk stratification output compatible with Lung-RADS classification for oncology handoff
- Fracture detection annotations on trauma MSK X-rays across 15 anatomies, processed in under a minute per scan
- TB patient tracking dashboard via qTrack showing screening outcomes, GeneXpert referral rates, and treatment initiation across a programme cohort
- PACS-integrated DICOM output overlays that route into existing radiology information systems without requiring separate viewer installation
- Regulatory-ready audit logs and performance dashboards for site-level quality monitoring and compliance reporting
ASEAN Perspective
Qure.ai in Southeast Asia
Qure.ai has significant ASEAN footprint anchored by tuberculosis control programmes: qXR is actively deployed in the Philippines (partnership with PBSP and Siemens Healthineers for mobile X-ray TB screening in high-burden cities) and has been used in Vietnam as part of the "Double X" strategy combining AI chest X-ray with GeneXpert, screening over 96,000 participants between 2020 and 2022. The platform holds regulatory approvals in ASEAN nations and is referenced in Southeast Asian public-health programmes supported by USAID and the Stop TB Partnership. For APAC enterprise buyers the data-residency question is material: Qure.ai supports on-premise deployment of its models (confirmed for qMSK and stated for cloud-or-on-premise options across products), which can satisfy data localisation requirements in markets such as Indonesia (PDPl) and Thailand (PDPA), though buyers should contractually confirm where training data and inference logs are processed. The January 2026 Gates Foundation POCUS grant explicitly names sub-Saharan Africa and Southeast Asia as priority regions, signalling continued investment in the region.
Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations in 85+ countries) that few competitors match. Its core products — qXR for chest pathology and qER for head CT triage — have been validated in peer-reviewed studies including publications in The Lancet, and the WHO has twice cited qXR in its official TB screening guidelines. For healthcare systems in lower-resource environments the cost-effectiveness argument is well-documented: independent evaluations in India show measurable increases in TB detection rates alongside reduced per-case diagnostic costs.
The main caveats are practical: pricing is fully opaque and negotiated on enterprise terms, which makes budget planning difficult for smaller hospital systems or NGOs without procurement support. Integration depth varies by site — Qure.ai connects via DICOM and PACS but implementation timelines and on-premise deployment complexity depend heavily on the local IT environment. The product portfolio covers radiology and emerging POCUS, but does not yet extend to pathology slides, endoscopy, or other imaging modalities competitors are pursuing. For organisations already operating within Qure.ai's disease focus areas (TB, lung cancer, stroke, trauma), the clinical evidence and global support network represent a compelling proposition; for others, the narrower scope is a limitation to weigh.
What people say
Qure.ai has exactly one review on G2 — not because the product is unproven, but because enterprise radiology-AI sales go through hospital procurement, not software marketplaces. The real evidence sits in peer-reviewed literature: qXR's tuberculosis-detection sensitivity has been validated against WHO benchmarks, and the WHO has cited qXR twice in its own TB screening guidance, an endorsement almost no radiology-AI competitor can claim.
The January 2026 Gates Foundation grant is the clearest signal of where the company is headed next — AI-powered point-of-care ultrasound for TB and pneumonia screening in low-resource settings, aimed at cutting diagnosis time from roughly two weeks to one or two days, plus an open-source multimodal lung-health database. That sits alongside a regulatory portfolio that keeps growing: 26 FDA-cleared indications across 9 products as of February 2026, deployment across 4,800+ sites in 105+ countries, and studies published in The Lancet and Scientific Reports backing the accuracy claims.
The recurring complaint, consistent across buyer forums and industry commentary, is pricing opacity — Qure.ai negotiates enterprise-only, with nothing published, which makes budget planning hard for smaller hospitals or NGOs without a procurement team. Clinical staff in high-burden TB programs report the tradeoff is worth it: a pre-read in seconds versus a multi-day wait for a radiologist.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Qure.ai holds 26 FDA-cleared indications across 9 products — more FDA clearances for lung cancer AI than any other company in the US as of 2025.
- The company's qXR chest X-ray AI is cited twice in the WHO's official TB screening guidelines, giving it quasi-official status in global public health programmes.
- TIME Magazine named Qure.ai to its 100 Most Influential Companies of 2025 list in the Pioneer category, alongside pharmaceutical giants like Gilead and Vertex.
- In January 2026 the Bill and Melinda Gates Foundation awarded Qure.ai a multimillion-dollar grant to build AI-powered point-of-care ultrasound, with plans to release a large open-source multimodal lung health database as part of the project.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Qure.ai's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Qure.ai unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Qure.ai directly →
Spotted something out of date? Suggest an update →
Related reading
More in Healthcare
